Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers

On May 2, 2019 Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, reported the start of an open-label (NCT03909152) basket study to evaluate the efficacy and safety of Apristor (onapristone extended release) in advanced gynecological tumors that are progesterone receptor positive (PgR+) (Press release, Context Therapeutics, MAY 2, 2019, View Source [SID1234535585]). Rachel N. Grisham, MD of Memorial Sloan Kettering Cancer Center is the study’s Primary Investigator.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 2 trial will include patients who have different PgR+ solid tumors in advanced stages, including low grade serous ovarian, granulosa cell, and endometrioid endometrial cancer, who have received prior chemotherapy treatment. The progesterone receptor antagonist Apristor will be assessed in up to 84 cancer patients. The primary endpoint will be overall response rate (ORR), which is the proportion of patients who have either a complete or partial response. To further characterize the activity of Apristor, secondary endpoints will include duration of response, clinical benefit rate, and progression-free survival (PFS). In addition, this study will evaluate the safety and pharmacological profile of Apristor in these patients, as well as biomarker analyses to explore predictive factors of response to Apristor. Preliminary trial results are expected in mid-2020.

"Currently, there are limited therapeutic options to treat these cancers in the advanced setting. Recent preclinical findings, together with Phase 1 study results in patients with advanced PgR+ ovarian and endometrial cancers, give us reason to believe that Apristor can help these women with PgR+ gynecological cancers," said Tarek Sahmoud, MD, PhD, Chief Medical Officer of Context Therapeutics. 1,2 "We believe Apristor can make a meaningful difference for patients in the trial."

For more information about the trial being conducted, please visit: View Source

About Apristor

Apristor (onapristone extended release) is an investigational new drug that is an orally administered full progesterone receptor antagonist. Currently, there are no approved therapies that selectively target PgR+ cancers. In a recent Phase 1 trial, Apristor was well tolerated and exhibited clinical benefit in heavily pretreated patients with PgR+ endometrial, ovarian and breast cancer. Preclinical data suggest that Apristor has anticancer activity by blocking the activation of progesterone receptor signaling by progesterone and/or mitogenic growth factors, inhibiting mammosphere formation and downregulating gene signatures associated with cancer stem cell mobilization and metastasis3,4.

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

On May 2, 2019 Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, reported the pricing of its underwritten public offering of 7,843,138 American depositary shares ("ADSs"), each representing one ordinary share of the Company, at a price of US$25.50 per ADS (Press release, Zai Laboratory, MAY 2, 2019, View Source [SID1234535653]). The offering was upsized from the previously announced offering size of 5,000,000 ADSs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The gross proceeds to Zai Lab from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately US$200.0 million. In addition, Zai Lab has granted the underwriters a 30-day option to purchase up to an additional 1,176,470 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 7, 2019, subject to customary closing conditions.

J.P. Morgan, Citigroup, Jefferies and SVB Leerink are acting as joint book-running managers for the offering.

The ADS are offered pursuant to a shelf registration statement on Form F-3ASR, which became automatically effective upon filing with the U.S. Securities and Exchange Commission ("SEC") on March 29, 2019.

The offering is being made only by means of a prospectus supplement and an accompanying prospectus included in Form-3ASR. The registration statement on Form F-3ASR and the prospectus supplement are available at the SEC’s website at: View Source Copies of the prospectus supplement and the accompanying prospectus may be obtained from: (i) J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or email: [email protected], (ii) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146 (iii) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-821-7388, or by email at [email protected] or (iv) SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: 1-800-808-7525 ex. 6132 or email: [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale of ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Amgen And Syapse Enter Precision Medicine Collaboration In Oncology

On May 2, 2019 Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, reported a precision medicine collaboration in oncology (Press release, Amgen, MAY 2, 2019, View Source;p=RssLanding&cat=news&id=2396920 [SID1234535691]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will identify existing patients within the Syapse Learning Health Network that could be eligible for Amgen-sponsored clinical trials and seek to bring these trials to community health system sites. The companies will create opportunities for physicians and researchers within the Syapse Network to gain access to analytics, real-world evidence-based insights, and collaborative research opportunities. Amgen will have access to real-world evidence for potential use in regulatory filings in support of certain agreed upon development candidates in oncology. Amgen will also work with Syapse to develop real-world evidence standards to support the acceleration of therapies to market.

"As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients," said Mike Nohaile, senior vice president of Strategy, Commercialization and Innovation at Amgen. "Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care."

"Syapse and Amgen share a common vision of ensuring that all cancer patients, regardless of income or location, receive access to the best possible care," said Ken Tarkoff, chief executive officer at Syapse. "Through this collaboration and the strategic relationships we’ve built with community health systems globally, we aim to develop evidence of clinical utility that can be used to bring molecularly targeted treatments to market more quickly and ensure more diverse groups of patients can access them."

About Amgen Oncology
Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient’s life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the company’s history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

ViewRay Reports First Quarter 2019 Results

On May 2, 2019 ViewRay, Inc. (Nasdaq: VRAY) reported financial results for the first quarter ended March 31, 2019 (Press release, ViewRay, MAY 2, 2019, View Source [SID1234535709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Quarter 2019 Highlights:

Received 7 new orders for MRIdian systems totaling $42.8 million, compared to 3 orders totaling $21.2 million in the first quarter of 2018.
Total revenue of $20.3 million, primarily from 3 revenue units and 1 system upgrade, compared to $26.2 million, primarily from 4 revenue units and 1 system upgrade, in the first quarter of 2018.
Total backlog increased to $237.5 million as of March 31, 2019, from $212.3 million as of December 31, 2018.
Cash and cash equivalents were $145.8 million as of March 31, 2019.
"Our first quarter results are a solid start to the year and reflect progress on our commercial, innovation, and clinical pipelines," said Scott Drake, President and CEO. "We are well-positioned to execute in 2019 and are focused on becoming the standard of care in radiation oncology."

First Quarter 2019 Financial Results:

Total revenue for the three months was $20.3 million, compared to $26.2 million for the same period last year.

Total cost of revenue was $25.7 million, compared to $20.6 million for the same period last year. Total cost of revenue in the first quarter of 2019 was impacted by approximately $7.0 million of charges, primarily driven by higher than anticipated installation costs related to historical upgrade commitments. The $7.0 million includes $5.6 million of one-time charges and $1.4 million of expenses.

Total gross profit was $(5.4) million, compared to $5.6 million for the same period last year.

Total operating expenses were $25.0 million, compared to $16.9 million for the same period last year.

Net loss was $33.4 million, or $0.34 per share, compared to $7.5 million, or $0.11 per share, for the same period last year.

ViewRay had total cash and cash equivalents of $145.8 million at March 31, 2019.

Financial Guidance:

The Company is reiterating its financial guidance for the full year 2019. The Company anticipates 2019 total revenue to be in the range of $111 million to $124 million, and total cash usage to be in the range of $65-$75 million.

Conference Call and Webcast

ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8616638. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at www.viewray.com.

After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay’s corporate website, www.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until May 9, 2019. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8616638.

Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors

On May 1, 2019 Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, reported that it has made three key additions to its leadership team and Board of Directors (Press release, Repare Therapeutics, MAY 1, 2019, View Source [SID1234535504]). Maria Koehler, MD, PhD, is joining May 1st as Executive Vice President and Chief Medical Officer and will lead Repare’s transition to a clinical-stage company . Katina Dorton has joined as Executive Vice President and Chief Financial Officer and will lead financial, capital markets and administrative operations. Carol Schafer has been appointed to the Board of Directors as an independent director.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to make these important additions to our executive and governance leadership as Repare embarks on a clinically-driven path to bring important new cancer medicines to the patients who need them," said Lloyd M. Segal, President and Chief Executive Officer of Repare Therapeutics. Dr. Koehler and Ms. Dorton will be based in Repare’s offices in Cambridge, MA.

Maria Koehler

Dr. Koehler is a hematologist/oncologist with 20 years in pharmaceutical and biotechnology companies. She has experience in both early drug development and bringing new drugs to global markets, having developed strategies for all stages of cancer drug development and medical affairs. Prior to joining Repare, Dr. Koehler was Chief Medical Officer at Bicycle Therapeutics. Prior to Bicycle she was VP, Strategy and Innovation for Pfizer Oncology, spearheading major acquisitions and strategic oncology portfolio decisions. Dr. Koehler also served as Oncology Integrated Development Leader at Pfizer, where she led the clinical development of Pfizer’s first-in-class breast cancer medicine, Ibrance (palbociclib), first approved in 2015 and with sales of more than $4 billion in 2018.

Dr. Koehler received her MD and PhD from the Silesian Medical School in Poland and has co-authored over 150 publications, book chapters and patents.

Katina Dorton

Prior to joining Repare, Ms. Dorton was Chief Financial Officer of Avrobio (Nasdaq: AVRO), a clinical-stage gene therapy company. At Avro, Katina led the raise of $175M in equity capital, including the Company’s $114M IPO. Prior to Avro, Katina was Chief Financial Officer of Immatics Biotechnologies, a T-cell-based immuno-oncology company. Katina has more than 15 years of investment banking experience advising corporate clients and their boards on capital markets, fund raising, mergers and acquisitions, and other strategic transactions. She was a Managing Director at Morgan Stanley and a Managing Director at Needham & Co. She practiced law as an M&A and securities law attorney at Sullivan & Cromwell prior to her investment banking career. Katina currently serves as Lead Director at US Ecology (Nasdaq: ECOL), an environmental services company.

Katina holds a J.D. from the University of Virginia School of Law, an M.B.A. from George Washington University, and a B.A. from Duke University.

Carol Schafer

Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development. She most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, she was a Managing Director and equity capital markets sector head at J.P. Morgan. She currently sits on the Board of Directors of Idera Pharmaceuticals, Inc. (Nasdaq: IDRA). Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University.